miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3^rd Line Cetuximab and Irinotecan

• Jakob V. Schou ,

  Contributed equally to this work with: Jakob V. Schou, Simona Rossi

  * E-mail: j.schou@dadlnet.dk

  Affiliation Department of Oncology, Herlev University Hospital, Herlev, Denmark

  ⨯
• Simona Rossi ,

  Contributed equally to this work with: Jakob V. Schou, Simona Rossi

  Affiliation Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland

  ⨯
• Benny V. Jensen,

  Affiliation Department of Oncology, Herlev University Hospital, Herlev, Denmark

  ⨯
• Dorte L. Nielsen,

  Affiliation Department of Oncology, Herlev University Hospital, Herlev, Denmark

  ⨯
• Per Pfeiffer,

  Affiliation Department of Oncology, Odense University Hospital, Odense, Denmark

  ⨯
• Estrid Høgdall,

  Affiliation Department of Pathology, Herlev University Hospital, Herlev, Denmark

  ⨯
• Mette Yilmaz,

  Affiliation Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

  ⨯
• Sabine Tejpar,

  Affiliation Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium

  ⨯
• Mauro Delorenzi,

  Affiliations Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland, Department of Oncology, University of Lausanne, Lausanne, Switzerland, Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland

  ⨯
• Mogens Kruhøffer,

  Affiliation AROS Applied Biotechnology, Aarhus, Denmark

  ⨯
• Julia S. Johansen

  Affiliation Department of Oncology, Herlev University Hospital, Herlev, Denmark

  ⨯